Navigation Links
Catalent Expands Kansas City Clinical Storage and Secondary Packaging Capabilities to Meet Growing Demand for Cold Chain Services
Date:4/4/2017

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it had completed an expansion project at its Kansas City, Missouri, facility to significantly increase controlled-temperature storage capabilities for its clinical supply business.

The expansion has added 70,000 cubic feet of storage (2-8 degrees Celsius) at the site, representing a five-fold increase in controlled-temperature capacity. This is made up of a combination of both pallet and high density storage options to increase flexibility. In order to support growing customer demand, two secondary cold packaging areas have been added, with the option to add more as needed.

“Customers have benefitted from our Kansas City campus’ integrated analytical, oral solid manufacturing, and clinical supply services, and now we can offer them expanded cold storage and packaging services as well,” commented Tom Moon, General Manager of Clinical Supply Services at the site. “In the past 18 months, we seen an increase in the numbers of both large and small customers, and to meet this growing demand have nearly doubled our clinical supply workforce, as well as introducing additional shifts in both packaging and distribution.”

Catalent’s 450,000 square feet Kansas City facility provides a range of fully integrated support services, from development and analytical support through to packaging and distribution. In 2015, the site completed an investment project that expanded its high-potent and cytotoxic clinical drug packaging capabilities.

Catalent has also recently announced investment and expansions to its workforce in its clinical supply network at Bolton and Bathgate in the U.K., and in Singapore.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Read the full story at http://www.prweb.com/releases/2017/04/prweb14212984.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Catalent Wins Prestigious Clinical Supply Chain Excellence Award at BioPharma Asia Convention
2. Challenges and Innovation in Clinical Trial Supply to be Presented by Catalent Experts at Upcoming Conferences
3. Catalent to Host Workshop with Leading Biologics Experts on Advanced Protein Development and Delivery at Upcoming Drug Delivery Partnerships Conference
4. Innovative Strategies for the Development of Lipid-based Oral Medicines to be Presented by Catalent and Gattefossé at Forthcoming Workshop
5. Accelerated Biopharmaceutical Development through Strategic Analytical Partnerships to be Discussed by Catalent Expert at Upcoming WCBP Conference
6. Catalent to Develop Softgel Capsules for JOT’s Leading Orphan Disease Candidates
7. Catalent Biologics Collaborates with PATH Malaria Vaccine Initiative to Create Antibodies for Malaria Vaccine Research and Development
8. Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative: Helps Shape Better Supply Chain to Pharmaceutical and Healthcare Industries
9. The Challenges and Opportunities for Cannabis-Based Therapeutics: Catalent to Present at Upcoming Industry Conference
10. Innovative Developments in Bioavailability, Drug Delivery and Optimization of Drug Design to be Presented by Catalent Experts at AAPS Annual Convention
11. Catalent Expert Invited by Tufts University to Discuss Challenges and Innovative Clinical Supply Chain Solutions at DIA 2016 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... April 22, 2017 , ... ... PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of the Year, ... providing information destruction , recycling, and compliance services to businesses throughout ...
(Date:4/21/2017)... ... 2017 , ... Providing broad access to life-saving drugs and rewarding the innovators ... way to address this problem. , That was the message from Dana Goldman, PhD, ... the University of Southern California, who served as the keynote speaker for Western University ...
(Date:4/21/2017)... Wis. (PRWEB) , ... April 21, 2017 , ... ... today announced that its B-595 and B-7569 vinyl label materials ... identification and warning labels are tested to remain intact and legible, for use on ...
(Date:4/21/2017)... Maine (PRWEB) , ... April 21, 2017 , ... ... today announced it’s been named Agency of Record (AOR) for Theravent, Inc. ... or eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... an exciting new partnership with the highly regarded and well renowned Asian distributor, ... innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
(Date:4/18/2017)... Research and Markets has announced the addition ... their offering. ... devices market to grow at a CAGR of 6.35% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/18/2017)... , April 18, 2017  Spero Therapeutics, LLC, ... the treatment of bacterial infections, will present preclinical data ... treatment of multidrug resistant (MDR) Gram-negative infections at the ... (ECCMID) April 22-25, 2017 in Vienna, Austria ... ...
Breaking Medicine Technology: